European Commission approves Sandoz Rixathon ® to treat blood cancers and immunological diseases. Approval expected to broaden patient access to biologics and enable budget-constrained healthcare ...

The European Commission has approved Rixathon, a biosimilar of the cancer drug rituximab, for use in Europe, according to an announcement from Novartis, whose Sandoz division manufactures the ...

Rixathon ® is a biosimilar version of Roche’s MabThera ® (rituximab) and is approved for use in all the same indications, including non-Hodgkin’s lymphoma (follicular lymphoma and diffuse large B-cell ...

Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche’s Rituxan that generated $7.5 billion in 2016 sales. Sandoz, the ...

Roche faces bad news today for its third-top selling drug Rituxan after its cross-town rival Novartis won European approval for its biosimilar, adding to the pressure for the $7.3 billion blockbuster.

Novartis AG NVS announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon, a biosimilar version of Roche’s RHHBY MabThera in Europe. The biosimilar version ...

Sandoz has gained European approval for its biosimilar version of Roche's blockbuster MabThera/Rituxan (rituximab) to be called Rixathon. The approval comes hot on the heels of Celltrion’s Truxima, ...

ZURICH (Reuters) - Switzerland's Novartis increased pressure on Roche's ageing stable of big-selling drugs on Monday by becoming the latest company to win European approval for a cut-price version of ...

The European Commission approved Rixathon for use in all indications of its reference medicine, MabThera. Sandoz, a division of Novartis, announced on June 19, 2017 that the European Commission (EC) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Rixathon, a biosimilar to rituximab and ...

Holzkirchen, June 19, 2017 - Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European Commission (EC) has approved Rixathon ® (biosimilar ...

Sandoz has gained European approval for its biosimilar version of Roche's blockbuster MabThera/Rituxan (rituximab) to be called Rixathon. The approval comes hot on the heels of Celltrion’s Truxima, ...